Epidemiological Burden of Lower Limb Spasticity in Adults: A Systematic Review by Javed, Mamoona & Ali, Muhammad Haider
Journal of Medical Research and Innovation, Vol 4, Iss 1 Page 1 of 8 
Epidemiological Burden of Lower Limb Spasticity in 
Adults: A Systematic Review
Mamoona Javed, Muhammad Haider Ali
Department of Health Technology Assessment and Outcomes Research, Parim Evidencia Ltd., London, 
RM6 6AX, United Kingdom
Address for correspondence: Mamoona Javed, Department of Health Technology Assessment 
and Outcomes Research, Parim Evidencia Ltd., London, RM6 6AX, United Kingdom. 
E-mail: mamoonajav@gmail.com
Abstract
Background: The purpose of this study was to investigate the epidemiological burden of illness associated 
with adult lower limb spasticity (LLS) and its complications. Methods: A systematic search of MEDLINE 
and EMBASE identified nine studies published between November 2012 and July 2019 that assessed the 
epidemiological burden associated with LLS. Results: LLS was found to occur in one-third of adults after 
neuromyelitis optica spectrum disorder, one quarter to one-third with multiple sclerosis, one quarter to 
half with Parkinson’s disease and roughly half with stroke. LLS limits mobility and reduces the quality of life. 
LLS complications, especially injuries following falls, are a common occurrence. Conclusion: The evidence 
on the burden of LLS is surprisingly limited given the condition’s high prevalence among adults with 
common disorders, such as stroke. Further research is needed to explore the trends in the incidence and 
prevalence of LLS over time and across different geographical regions. The dearth of high-quality evidence 
for LLS suggests a lack of awareness of, and interest in, the problem, and therefore, the unmet need among 
patients and their carers.
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Introduction
Lower limb spasticity (LLS), a movement disorder 
often described as muscle overactivity, is caused 
by the damage to the portion of the brain or spinal 
cord. This damage alters the balance of signals 
between the nervous system and the muscles; 
hence, the condition is associated with various 
neurological conditions.[1] Spasticity is one of the 
most frequent symptoms associated with multiple 
sclerosis (MS).[2] However, it may be caused by 
traumatic brain injury (TBI), spinal cord injury (SPI), 
stroke, and other related conditions.[1] In addition 
to this, spasticity is a main feature in several rare 
conditions such as tropical and hereditary spastic 
paraparesis.[3] Spasticity can affect the entire 
body,[4] but LLS is generally worse because it affects 
mobility, balance, and independence along with 
adding burden on the carers.[5] Spasticity can lead 
to muscle contracture, joint stiffness, reduced 
range of movement, broken skin, and pain[6] and 
can significantly restrict patients’ mobility and 
functional ability, their activities of daily living and 
can diminish their quality of life.[7]
The incidence and prevalence of LLS vary 
geographically that its severity is associated with 
falls in persons with MS.[8] Distal paresis of the lower 
limb is considered an early predictor of spasticity in 
adults with ischemic stroke.[9] Although there are 
several common risk factors for spasticity, risk factors 
vary for various underlying conditions. For example, 
age is a risk factor for spasticity in stroke patients. 
Younger age at the time of stroke[10] is associated 
with the increased likelihood of spasticity. On the 
other hand, smoking is among common risk factors 
for spasticity. A history of smoking[11] is associated 
with an increased probability of spasticity. The most 
frequently reported symptom in spasticity is pain, 
and it increases with increasing age; however, there 
is no established correlation between spasticity and 
pain.[12]
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Management of spasticity depends on underlying 
pathologies. It is significantly different in patients 
with TBI due to behavioral and cognitive issues 
that affect their ability to participate in, or tolerate, 
treatment (e.g., their ability to follow instructions, 
monitor use of a spastic limb, or tolerate a 
cast).[6] The treatment of spasticity requires a 
multi-disciplinary approach and usually starts 
with physiotherapeutic approaches. However, a 
direct effect on abnormal muscle activity can only 
be achieved by pharmacological interventions. 
Systemically acting pharmacological interventions 
are used before employing locally acting drugs. In 
some cases, surgery is the final treatment option; 
however, it is hardly an option in the stroke 
population.[13]
The published research on the epidemiology of LLS 
is relatively rare. A systematic review published 
on this topic was back in 2013, which included 
literature between October 2002 and October 
2012.[14] We have not found any other systematic 
review to summarize the research conducted, 
on the epidemiology of LLS, after October 2012. 
Hence, our systematic review has considered the 
literature published between November 2012 and 
July 2019 to identify studies specifically on the 
epidemiological burden associated with adult LLS. 
LLS affects both children and adults; however, this 
systematic review focuses only on adults.
Aim and objective
The aim of this systematic review is to describe 
and quantify the size of the problem (LLS) and to 
highlight the evidence gap.
Methods
This systematic review was conducted to identify 
evidence assessing the epidemiological burden 
of LLS. Preferred reporting items for systematic 
reviews and meta-analyses, reported at http://
www.prisma-statement.org /statement.htm 
guidelines were followed throughout. We aimed 
to use a rigorous and transparent methodology to 
reduce bias in the selection of relevant studies.
Data sources and search strategy
We systematically reviewed the literature indexed 
in MEDLINE and EMBASE, published between 
November 2012 and July 2019, relating to the 
epidemiological burden associated with LLS in 
adults. The search strategy used is reported in the 
Supplementary Materials and was constructed 
from search terms relating to the epidemiological 
burden for spasticity, to the lower limb, and to the 
main underlying pathologies associated with LLS. 
The search was narrowed by applying filters to limit 
the studies only to adults, English language and 
human. The bibliography of each relevant article 
was cross-referenced with the search results to 
identify additional studies.
Study selection
The first 100 abstracts were screened independently 
by two researchers and any disagreements resolved 
by discussion. Each abstract was then screened by 
one researcher and included studies checked by 
another researcher. Inclusion criteria for study 
selection were primary research and systematic 
reviews relevant to adults with LLS from any cause, 
reporting epidemiological outcomes, published in 
English between 2012 and 2019. The inclusion and 
exclusion criteria are reported in full in Table 1 in 
Supplementary Materials.
The full texts were retrieved for all studies that 
definitely or possibly met the inclusion criteria 
for abstract screening. Full-text screening used 
the same inclusion criteria as abstract screening 
but focused on identifying studies with clinically 
relevant outcomes. The full-text screening was 
conducted independently by two researchers and 
disagreements were resolved by discussion. The 
methodological quality of included studies was 
assessed and documented based on the concise 
critical appraisal checklist reported in Table 2 in 
Supplementary Materials.
Data extraction
Data from the included studies were extracted into a 
pre-agreed template in MS Word by one researcher 
and all data extraction tables were checked by 
a second researcher. No statistical analysis was 
planned but the results were synthesized narratively 
to identify common themes and gaps in the evidence.
Results
The database search of MEDLINE and EMBASE 
identified 2357 citations, of which 447 were 
duplicates, leaving 1910 unique citations for 
screening. We identified many studies that reported 
on the management of spasticity in general, but the 
evidence base on LLS epidemiological burden was 
much smaller. A total of 25 articles were identified 
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Table 1: Inclusion and exclusion criteria
Category Inclusion criteria Exclusion criteria
Population Patients older than 18 years of age 
with LLS that could have resulted 
from any of the following underlying 
diseases
Stroke
MS
TBI Cerebral palsy
Others, for example, PD
Studies investigating patients without LLS
Studies on adolescents and children younger than 18 years 
of age with LLS
Epidemiologic 
outcomes
Prevalence and incidence of LLS due 
to different underlying pathologies, as 
listed above
Trends of LLS over time
Outcomes and prognosis of LLS
Health and social problems associated 
with LLS
Comorbidities associated with LLS
Articles without relevant data on any of the outcomes of 
interest
Studies on genetic profiling
Prevalence studies with fewer than ten participants
Articles investigating the efficacy and/or effectiveness 
of botulinum toxin or any other investigation in the 
treatment of LLS
Studies investigating the biomechanical factors associated 
with spasticity (e.g., electromyogram findings, joint angle, 
foot position, and muscle blood flow)
Studies assessing the validity of instruments used to 
measure spasticity
Study design Primary research including cohort 
studies, case–control studies, 
cross-sectional studies, case series, 
and randomized controlled trials 
(if available), database studies, and 
systematic reviews
Letters to the editor
Narrative reviews
Editorials
Expert opinions
Case studies
Year of 
Publication
November 2012 to July 2019 Studies prior to November 1, 2012 and after July 31, 2019
Language English language Non-English language
Filters applied: Human, adults. LLS: Lower limb spasticity, MS: Multiple sclerosis, TBI: Traumatic brain injury, PD: Parkinson’s disease
Table 2: Quality assessment criteria for included studies
Criterion Yes Partly, or 
unclear
No
1. Methodology
  Is the study methodology appropriate for the aims of the study?
2 1 0
2.  Transparency of reporting
  Are all relevant outcomes reported clearly in the paper?
2 1 0
3.  Sample size
 Were enough patients recruited into the study to make the conclusions credible?
2 1 0
4.  Conclusions
 Are the conclusions of the paper supported by the results reported?
2 1 0
as potentially meeting the inclusion criteria and 
were retrieved as full texts, and nine of these were 
subsequently included in the review [Figure 1].
Nine studies included in this systematic review all 
described primary research on the epidemiological 
burden of LLS in adults with varying underlying 
pathologies. Five of these studies used observational 
cross-sectional methodologies; two studies used 
case–control methodology, one was a prospective 
cohort study and one was a systematic review. All 
studies reported epidemiologic outcomes, with two 
reporting multiple outcomes and one systematic 
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review of observational studies. The study 
characteristics of included studies are summarized 
in Table 3.
Eight studies reported on the prevalence of LLS in 
cohorts with a particular underlying disease. The pilot 
results of the national SONAR registry study reported 
the incidence of LLS in stroke patients. These are 
summarized in Table 4. Three studies focused on 
LLS in Parkinson’s disease (PD) patients, three in 
MS patients, and one each in stroke, neuromyelitis 
optica spectrum disorder, and multiple etiologies 
patients. There was considerable variation between 
studies on the instruments used to measure LLS. The 
Modified Ashworth Scale was the only instrument 
reported as being used in more than one study.
The incidence of LLS in patients with ischemic 
stroke in the internal carotid artery territory was 
44.9% due to the first-ever stroke in the first 10 days 
after stroke onset.[15] The LLS severity level was 
varied among patients, 32.5% presented with mild 
neurological deficit while 27% were bedridden.[15]
Matsubara et al. had studied spasticity with various 
underlying pathologies. The prevalence of LLS 
in patients with PD and multiple system atrophy 
(MSA) was 12.7% and 5.8%, respectively. About 
50% of PD patients had bilateral spasticity and 50% 
PD patients had unilateral spasticity.[16]
Atlas of Social Protection Indicators of Resilience 
and Equity (ASPIRE) is the largest existing 
international database on spasticity, which 
Figure 1: Preferred reporting items for systematic reviews and meta-analyses flow diagram. 
LLS: Lower limb spasticity
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prospectively evaluates demographics and clinical 
characteristics of spasticity across multiple 
etiologies including stroke, MS, other etiologies, 
cerebral palsy, TBI, and SPI. The database includes 
patients who have a disability and a caregiver. The 
prevalence of LLS in ASPIRE database patients was 
reported 84.2%.[17] These data on the prevalence 
of LLS in different underlying pathologies are 
summarized in Table 3.
Matsubara et al. had studied spasticity with various 
underlying pathologies. The prevalence of LLS in 
patients with PD and corticobasal degeneration 
was 22.2% and 50%, respectively. However, 
the prevalence of LLS in MSA and progressive 
Table 3: Characteristics of studies included in this review
References Underlying pathology Country Participants 
(n)
Male Focus of study
Francisco et al.[17] Multiple etiologies International 727 348 Prevalence
Dornak et al.[15] Stroke Czech Republic 256 157 Incidence
Matsubara et al.[16] PD Japan 63 NR Prevalence
Matsubara et al.[16] MSA Japan 17 NR Prevalence
Matsubara et al.[16] PSP Japan 11 NR Prevalence
Yang et al.[19] PD China - - Prevalence
Matsubara et al.[18] PD Japan 27 NR Prevalence
Matsubara et al.[18] MSA Japan 5 NR Prevalence
Matsubara et al.[18] PSP Japan 2 NR Prevalence
Matsubara et al.[18] CBD Japan 2 NR Prevalence
Al-hussainy and Hatem[20] MS Iraq 110 36 Prevalence
Barzegar et al.[23] NOSD Iran 122 NR Prevalence
Carnero et al.[21] MS Argentina 427 NR Prevalence
Lebrato Hernández et al.[22] MS Spain 120 NR Prevalence
MS: Multiple sclerosis, NOSD: Neuromyelitis Optica Spectrum Disorder, MSA: Multiple system atrophy, PSP: Progressive supranuclear 
palsy, CBD: Corticobasal degeneration, PD: Parkinson’s disease
Table 4: Prevalence of lower limb spasticity in different conditions
Study Country n Muscle groups Prevalence of LLS (%)
Multiple etiologies
Francisco et al.[17] International 727 Any LL 84.2
Stroke
Dornak et al.[15] Czech Republic 256 Any LL 46.9
PD
Matsubara et al.[16] Japan 91 Any LL 49.2
Yang et al.[19] China - Leg 14.0
Matsubara et al.[18] Japan 36 Any LL 34.3
MS
Al-hussainy and Hatem[20] Iraq 110 Leg 17.3
Carnero et al.[21] Argentina 189 Leg 29.1
Lebrato Hernández et al.[22] Spain 120 Leg 23.3
NOSD
Barzegar et al.[23] Iran 40 Leg 26.8
NOSD: Neuromyelitis Optica Spectrum Disorder, LLS: Lower limb spasticity, MS: Multiple sclerosis, PD: Parkinson’s disease
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supranuclear palsy patients was 0%.[18] The authors 
did not find any evidence on the comparative rate of 
prevalence of bilateral spasticity and unilateral LLS. 
No studies reported on the severity of spasticity in 
patients with PD.
Pooled prevalence of LLS in PD patients was 14%. 
The prevalence was lower in Asia (12%) than outside 
of Asia (16%). The authors found a relatively higher 
prevalence in females (13%) than in males (11%).[19] 
The prevalence of LLS in MS patients ranged from 
17.3% to 29.1% in our systematic review.[20-22]
Discussion
The epidemiologic burden of LLS is significantly high 
but may change over time as the epidemiology of 
the underlying conditions changes. For example, 
there is evidence that the prevalence of stroke has 
fallen in developed countries[24] but may increase 
again in the future with aging of the population.[25] 
The prevalence of stroke and cardiovascular disease 
is increasing, especially in developing countries. 
Increasing the use of motor vehicles and lifestyle 
changes may lead to an increase in people with 
LLS. Although advanced medical technologies have 
improved the survival after predisposing events, 
this improved survival may increase LLS prevalence, 
we did not find any study providing the evidence of 
an association between long-term survival and LLS.
The prevalence of spasticity vary widely based on 
underlying conditions. The prevalence of spasticity 
following stroke is between 17% and 46%,[26] 
however, post-stroke LLS indicated in our research is 
46.9%, which is marginally higher from the previous 
research and maybe contributed by chance only. 
The prevalence of spasticity in PD patients ranges 
from 0% to 38%.[19]
There is an association between LLS and falls. 
A study conducted on MS patients found that the 
severity of knee flexors and ankle plantar flexors 
spasticity was significantly higher in the fallers 
compared to non-fallers.[8] Injuries after fall due 
to LLS are increasing in elderly people with an 
increase in aging populations, especially in Western 
countries.[27] The evidence of LLS complications 
including falls and injuries after fall is scarce. 
We have found only one study concluding the 
association between LLS and falls in MS patients. 
A most common complaint by the patients is pain; 
however, we did not find any clear association 
between LLS and occurrence of pain.
International studies on the prevalence of LLS are 
scarce. We found only one international study on 
the prevalence of LLS and associated burden of 
illness. We did not find any specific LLS patterns or 
trends based on geographical location or underlying 
conditions. All the included studies meet our quality 
assessment criteria.
Evidence gaps
We found limited evidence on the burden of illness 
associated with LLS. This is partly because we focused 
on studies published between November 2012 and 
July 2019 to ensure that the review reflects the most 
recent disease epidemiology. However, we believe 
that there is relatively little published research on 
the epidemiology and impact of LLS, during this 
approximately 7 years period, compared to other 
medical conditions. Moreover, we found only one 
study on the incidence of LLS, which is astounding 
especially for the countries who have national 
health-care databases. This indicates that LLS either 
does go unrecognized by health-care professionals 
or is not considered as an individual illness.
Substantial gaps in this systematic review need to 
be addressed through conducting:
• More research to determine the prevalence 
and incidence of LLS, and the trends in the 
incidence and prevalence of LLS over time and 
across different geographical regions
• More research to understand the association 
of LLS and its complications, regardless of the 
underlying causative mechanisms.
Conclusion
Our research has indicated that a substantial 
proportion of adults with stroke, MS, PD, cerebral 
palsy, and other motor neuron disorders may 
have LLS. However, we cannot be sure of the 
overall burden of LLS due to the lack of global 
epidemiological data. Further research on the 
evidence gap areas is necessary for a greater 
understanding of the problem.
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Search strategy
ab = abstract; ti = title; sh = MeSH: Medical subject 
heading (MEDLINE medical index term)
Filters: Humans, English, Publication dates: 
November 1, 2012 to July 31, 2019.
1. Epidemiologic string
1. Incidence.ti,ab
2. prevalence.ti,ab
3. incidence.sh
4. prevalence.sh
5. epidemiology.sh
6. “epidemiological data”.ti,ab
7. epidemiology.ti,ab
8. epidemiologic.ti,ab
9. epidemiological.ti,ab
10. “unmet need”.ti,ab
11. access.ti,ab
12. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 
9 OR 10 OR 11
2. Disease string
1. Spasticity.ti,ab
2. palsy.ti,ab
3. rigidity.ti,ab
4. hemiparesis.ti,ab
5. hemiplegia.ti,ab
6. “brain injury”.ti,ab
7. stroke.ti,ab
8. “multiple sclerosis”.ti,ab
9. hypertonic*.ti,ab
10. “cerebral palsy”.ti,ab
11. botulinum.ti,ab
12. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 
9 OR 10 OR 11
13. leg.ti,ab
14. “lower limb”.ti,ab
15. calf.ti,ab
16. thigh.ti,ab
17. knee.ti,ab
18. foot.ti,ab
19. ankle.ti,ab
20. hip.ti,ab
21. 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19 
OR 20
22. 12 AND 21
3. 1 AND 2
4. 3 NOT (child)
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